Technology Is Helping Address Barriers in Women’s Healthcare
Medical innovation is not always about discovering an entirely new treatment.
Sometimes, meaningful progress comes from making existing diagnostic technologies more accessible to the people who need them.
Cervical cancer screening is one area where access remains an important challenge.
Although routine screening can help identify high-risk HPV infections and detect cervical abnormalities, many patients face barriers that prevent them from receiving recommended testing.
On October 23, 2026, Labcorp and Waters Corporation announced a partnership designed to expand access to advanced HPV testing across the United States.
The companies plan to introduce the FDA-approved BD Onclarity HPV Assay through Labcorp’s nationwide laboratory network beginning in late 2026.
What Is the BD Onclarity HPV Assay?
Human papillomavirus, commonly known as HPV, is a group of viruses that includes types associated with an increased risk of cervical cancer.
HPV testing helps healthcare professionals identify infections that may require additional monitoring or follow-up.
The BD Onclarity HPV Assay provides extended genotyping information, allowing clinicians to distinguish among several high-risk HPV types.
This additional information can help support risk-based decisions about patient care.
According to the companies, the assay individually identifies six high-risk HPV genotypes and provides grouped results for additional types.
The test is FDA-approved, and the companies intend to expand access through Labcorp’s laboratory infrastructure.
Making Screening More Accessible
One of the partnership’s most significant elements is its focus on collection options.
Traditional cervical screening frequently requires an appointment involving sample collection by a healthcare professional.
For some patients, scheduling difficulties, transportation, privacy concerns, and other barriers can make routine screening challenging.
Labcorp and Waters plan to support clinician-collected and qualifying self-collected samples.
Their announcement includes options involving clinical settings, patient service centers, and at-home collection.
Self-collection is not necessarily appropriate for every patient or screening circumstance.
Patients should follow current medical guidance and the instructions associated with the authorized test and collection method.
The companies expect the expanded offering to become available by the end of 2026.
The announcement does not establish that every collection option is already available nationwide.
The Technology Behind Modern Diagnostics
Advanced molecular diagnostics involve several scientific disciplines.
Molecular biologists study biological markers that can help identify disease-related processes.
Laboratory scientists develop and operate testing methods.
Biomedical engineers contribute to diagnostic technologies and laboratory systems.
Data specialists and software engineers help manage the information generated by testing.
Regulatory professionals work to ensure that medical products and laboratory processes meet applicable requirements.
These roles demonstrate how innovation in women’s health depends on collaboration across multiple STEM fields.
Why Women’s Health Innovation Matters
Historically, some areas of women’s health have received less research attention and investment than their importance warrants.
Expanding access to preventive healthcare requires more than technological innovation alone.
It also involves understanding patient experiences, addressing access barriers, improving healthcare delivery, and ensuring that technologies are appropriately evaluated.
The Labcorp–Waters partnership illustrates how diagnostic innovation and healthcare infrastructure can work together.
However, the impact of the planned expansion will depend on implementation, patient access, clinical appropriateness, and adoption.
Looking Ahead
Labcorp and Waters expect to begin offering the BD Onclarity HPV Assay through the expanded arrangement by the end of 2026.
As the rollout progresses, important questions will include which collection options are available, who is eligible, and how patients can access testing.
For women working in STEM, the announcement highlights opportunities to contribute to biotechnology, medical diagnostics, research, engineering, and healthcare innovation.
It also reinforces a broader principle: developing better healthcare technology is only part of the challenge.
Ensuring that people can access and benefit from that technology is equally important.
Sources & Further Reading
Waters Corporation — October 23, 2026 Partnership Announcement
Labcorp — Cervical Cancer Screening Information
Discover more from Fems in STEM
Subscribe to get the latest posts sent to your email.
